Straits Times Index
3,265.05 -34.99 (-1.06%) Nikkei
38,268.11 -566.99 (-1.46%) Hang Seng
18,355.89 -123.48 (-0.67%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,650.04 -948.34 (-1.49%) CMC Crypto 200
1,297.62 +2.95 (+0.23%)
BioMarin Pharmaceutical Inc. (BMRN)
After hours:
| Previous close | 82.10 |
| Open | 82.40 |
| Bid | 82.48 x 500 |
| Ask | 82.72 x 400 |
| Day's range | 81.81 - 83.02 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,543,108 |
| Market cap | 15.68B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 77.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
- PR Newswire
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
- PR Newswire
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
